Acquired drug resistance: We can do more than we think!

Clinical Infectious Diseases

Volumn 60, Issue 6, 2015, Pages 969-970

  Alffenaar, Jan Willem C ^a   Gumbo, Tawanda ^b   Aarnoutse, Rob E ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

AREA UNDER THE CURVE; DRIED BLOOD SPOT TESTING; DRUG MONITORING; DRUG QUALITY; DRUG RESISTANCE; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; HUMAN; LETTER; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; ROOM TEMPERATURE; DRUG EFFECTS; FEMALE; MALE; MICROBIOLOGY; MULTIDRUG RESISTANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84930268832     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu1146     Document Type: Letter

References (10)

1. Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59:1049-63.
2. Daley CL, Horsburgh CR Jr. Treatment for multidrug-resistant tuberculosis: it's worse than we thought. Clin Infect Dis 2014; 59:1064-5.
3. Gumbo T, Louie A, Deziel MR, Drusano GL. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 2005; 49:3178-81.
4. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190:1642-51.
5. Alffenaar JW, van Altena R, Bökkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009; 49:1080-2.
6. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013; 13:27-35.
7. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to betweenpatient pharmacokinetic variability. J Infect Dis 2011; 204:1951-9.
8. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55:169-77.
9. Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38:888-94.
10. Vu DH, Koster RA, Alffenaar JW, Brouwers JR, Uges DR. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:1063-70.